SG Americas Securities
RAPT

SG Americas Securities’s RAPT Therapeutics RAPT Stock Holding History

SG Americas Securities’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-6,656
Closed -$84K – 3701
2024
Q4 		$84K Buy
6,656
+5,330
+402% +$67.7K ﹤0.01% 2788
2024
Q3 		$21K Buy
+1,326
New +$26.8K ﹤0.01% 3343
2024
Q1 		– Sell
-1,225
Closed -$244K – 3356
2023
Q4 		$244K Buy
+1,225
New +$152K ﹤0.01% 1984
2023
Q2 		– Sell
-1,632
Closed -$240K – 2996
2023
Q1 		$240K Buy
+1,632
New +$330K ﹤0.01% 2297
2022
Q4 		– Sell
-794
Closed -$153K – 3319
2022
Q3 		$153K Buy
+794
New +$150K ﹤0.01% 2539
2022
Q1 		– Sell
-498
Closed -$146K – 3341
2021
Q4 		$146K Sell
498
-19,533
-98% -$5.22M ﹤0.01% 2842
2021
Q3 		$4.98M Buy
20,031
+10,810
+117% +$2.86M 0.02% 541
2021
Q2 		$2.35M Buy
+9,221
New +$1.72M 0.01% 1025
2020
Q3 		– Sell
-742
Closed -$172K – 3308
2020
Q2 		$172K Buy
+742
New +$115K ﹤0.01% 2973

Other funds holding RAPT

MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

SG Americas Securities's RAPT Position: Q1 2025 in Review

SG Americas Securities sold out of RAPT Therapeutics (RAPT) in Q1 2025, closing a stake of 6,656 shares — an estimated $84K sold.

SG Americas Securities first reported a position in RAPT in Q2 2020 and held it in 9 quarters. The position peaked at $4.98M in Q3 2021. 92 funds tracked by Wall St. Rank hold RAPT as of Q1 2025.

  • SG Americas Securities reported no remaining RAPT Therapeutics position as of Q1 2025 after selling out during the quarter.
  • SG Americas Securities sold 6,656 RAPT Therapeutics shares in Q1 2025, an estimated $84K.
  • SG Americas Securities first reported a position in RAPT Therapeutics in Q2 2020 and held it in 9 quarters.
  • SG Americas Securities's RAPT Therapeutics position peaked at $4.98M in Q3 2021.
  • 92 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2025.

Based on SG Americas Securities's 13F filing for Q1 2025, filed 15 Apr 2025.